Novartis (NVS) Q2 2026 Earnings

Yes. Novartis reported Q2 2026 earnings of $2.41 a share on Jul 21, 2026, beating the $2.15 consensus estimate by 12.2%. Revenue was $14.4B against a $14.1B estimate.

Novartis delivered a clear beat across both top and bottom lines in Q2 2026, with adjusted EPS of $2.41 topping the $2.15 consensus by 12.21% and revenue of $14.41 billion edging past estimates by 2.50%, even as reported net sales slipped 2.9% year over year. The headline story was a tale of two portfolios: surging specialty brands including Kisqali, up 44%, Scemblix, up 89%, Pluvicto, up 43%, and Leqvio, up 61%, helped absorb a punishing 50% collapse in Entresto sales to $1.18 billion as U.S. generic competition accelerated. IFRS net income fell 19% to $3.26 billion, weighed down by a tax rate that climbed to 23.7% from 11.2% a year earlier due to intercompany transaction effects, alongside restructuring costs that surged to $472 million. Net debt ballooned to $39.39 billion from $21.95 billion at year-end, reflecting the $12 billion Avidity Biosciences acquisition, though the company's pipeline continued to advance, with a recent FDA approval broadening Pluvicto's eligible patient population into earlier-stage prostate cancer.